Melissa Malhame, speaking at World Influenza Congress Europe 2011

Melissa Malhame,
Director Marketing & Product Management
Dynavax Technologies

Melissa Malhame., MBA is the Sr. Director of Marketing and Product Management at Dynavax Technologies. Ms. Malhame holds a MBA from Cornell University's Johnson Graduate School of Management in marketing and general management. Melissa has worked during the past fifteen years in various vaccine marketing, sales and business development positions of increasing responsibility with Merck Vaccine Division, and Dynavax Technologies. Her responsibilities have included Market Research and Business Development, Promotion Management, Physician and Institutional Sales and Product Management with Merck. At Dynavax Melissa has had responsibility as Project Leader of their lead Phase 3 hepatitis B vaccine, HEPLISAV, including the negotiation and management of a collaboration between Dynavax and Merck for development of the vaccine.

Appearing:

Congress Day 2 – Wednesday 7th December 2011

4.10pm

Continued development of Dynavax’s universal influenza vaccine

What have been the lessons learned from the phase 1a and phase 1b clinical studies?
What are the immunological properties of the N8295 universal influenza candidate?
How is the development and design of a proof of concept study progressing?
What is the future of the universal influenza vaccine as a novel component or in combination?

Melissa Malhame,

Director Marketing & Product Management,
Dynavax Technologies

Sponsor World Influenza Congress Europe 2011 ›

Silver Sponsor